Britannia Life Sciences Balance Sheet Health
Financial Health criteria checks 2/6
Britannia Life Sciences has a total shareholder equity of CA$6.2M and total debt of CA$6.5M, which brings its debt-to-equity ratio to 104.4%. Its total assets and total liabilities are CA$21.7M and CA$15.5M respectively. Britannia Life Sciences's EBIT is CA$829.3K making its interest coverage ratio 0.6. It has cash and short-term investments of CA$742.4K.
Key information
104.4%
Debt to equity ratio
CA$6.50m
Debt
| Interest coverage ratio | 0.6x |
| Cash | CA$742.36k |
| Equity | CA$6.23m |
| Total liabilities | CA$15.50m |
| Total assets | CA$21.73m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: L020's short term assets (CA$2.5M) do not cover its short term liabilities (CA$10.9M).
Long Term Liabilities: L020's short term assets (CA$2.5M) do not cover its long term liabilities (CA$4.6M).
Debt to Equity History and Analysis
Debt Level: L020's net debt to equity ratio (92.5%) is considered high.
Reducing Debt: Insufficient data to determine if L020's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable L020 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: L020 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 29.5% per year.